Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia
2019
β-thalassemia is a hereditary disorder with limited approved treatment options; patients experience anemia and its complications, including iron overload. The study aim was to determine whether luspatercept could improve anemia and disease complications in patients with β-thalassemia. This open-label, nonrandomized, uncontrolled study consisted of a 24-week dose-finding and expansion stage (initial stage) and a 5-year extension stage, currently ongoing. Sixty-four patients were enrolled; 33 were non–transfusion dependent (mean hemoglobin,
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
50
Citations
NaN
KQI